E L J Hoogervorst
Overview
Explore the profile of E L J Hoogervorst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toorop A, Wessels M, Gelissen L, Hoitsma E, Zeinstra E, van Rooij L, et al.
J Neurol Sci
. 2024 Jun;
462:123102.
PMID: 38925067
Background And Objectives: Wearing-off symptoms during natalizumab treatment in multiple sclerosis are characterized by an increase of MS-related symptoms prior to natalizumab administration. The influence of extended interval dosing (EID)...
2.
Kremer I, Jongen P, Evers S, Hoogervorst E, Verhagen W, Hiligsmann M
BMC Med Inform Decis Mak
. 2021 Apr;
21(1):123.
PMID: 33836742
Background: Since decision making about treatment with disease-modifying drugs (DMDs) for multiple sclerosis (MS) is preference sensitive, shared decision making between patient and healthcare professional should take place. Patient decision...
3.
Daniels K, van der Nat P, Frequin S, van der Wees P, Biesma D, Hoogervorst E, et al.
Mult Scler Int
. 2020 Jul;
2020:5463451.
PMID: 32607256
Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of...
4.
Jeung L, Smits L, Hoogervorst E, van Oosten B, Frequin S
Mult Scler Relat Disord
. 2020 Feb;
40:101978.
PMID: 32062445
A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in...
5.
Liedorp M, van der Flier W, Hoogervorst E, Scheltens P, Stam C
Dement Geriatr Cogn Disord
. 2008 Dec;
27(1):18-23.
PMID: 19088474
Aim: To describe associations of abnormalities in the electroencephalogram (EEG) with the most prevalent diagnoses in a memory clinic cohort. Methods: Associations between visual EEG findings and diagnoses in 1,116...
6.
Visschedijk M, Uitdehaag B, Klein M, van der Ploeg E, Collette E, Vleugels L, et al.
Neurology
. 2004 Dec;
63(11):2046-50.
PMID: 15596748
Objective: To determine the value of health-related quality of life (HRQoL) to predict change in disability status in patients with multiple sclerosis (MS). Methods: Over a 5-year period, data were...
7.
Hoogervorst E, Zwemmer J, Jelles B, Polman C, Uitdehaag B
Mult Scler
. 2004 Oct;
10(5):569-74.
PMID: 15471375
Objective: To validate the newly developed Multiple Sclerosis Impact Scale (MSIS-29) in a large, well characterized, independent group of MS patients by investigating the relation between the MSIS-29 and the...
8.
Hoogervorst E, Kalkers N, Cutter G, Uitdehaag B, Polman C
Mult Scler
. 2004 Feb;
10(1):55-60.
PMID: 14760953
Objective: To prospectively characterize the relation between two-year changes in functional impairment as measured by the Multiple Sclerosis Functional Composite (MSFC) and changes in patient perceived disability as measured by...
9.
Teunissen C, Dijkstra C, Polman C, Hoogervorst E, von Bergmann K, Lutjohann D
Neurosci Lett
. 2003 Jul;
347(3):159-62.
PMID: 12875910
The serum concentration of 24S-hydroxycholesterol reflecting brain cholesterol turnover may be a possible marker for neurodegeneration and demyelination in multiple sclerosis. Serum was analyzed for cholesterol precursors and oxysterols in...
10.
Killestein J, Hoogervorst E, Reif M, Blauw B, Smits M, Uitdehaag B, et al.
J Neuroimmunol
. 2003 Apr;
137(1-2):140-3.
PMID: 12667658
Cannabinoids can modulate the function of immune cells. We here present the first human in vivo study measuring immune function in 16 MS patients treated with oral cannabinoids. A modest...